路透香港5月15日 - 总部位于新加坡的微小核糖核酸（miRNA）技术公司--Mirxes Holding Company Limited2629.HK：
* 计划发售46,620,000股股份，每股发售价23.3港元，预期股份于5月23日开始于联交所买卖
* 我们的核心产品GASTROClearTM为一个由12种miRNA生物标志物组成的用于胃癌筛查的基于血液的miRNA检测组
* 与北京浔瑞及Evergreen Gate订立基石投资协议，涉资5,792万美元（或约4.49亿港元）；Evergreen Gate为复星国际0656.HK旗下企业
公告全文，请点击此处
(Reporting By Alison Lui)
((alison.lui@thomsonreuters.com; +852 3462 7749;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.